linjc16/ctgov huggingface dataset:
Association of Oral Helicobacter Pylori Infection With Gastric Helicobacter Pylori Infection

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to investigate the association between oral Helicobacter pylori infection and gastric Helicobacter pylori infection. Patients who were tested for gastric Helicobacter pylori were tested for oral Helicobacter pylori at the same time, and were divided into four groups according to the test results to compare the positive rate of oral Helicobacter pylori.

Official Title
-----------------
Association of Oral Helicobacter Pylori Infection With Gastric Helicobacter Pylori Infection

Conditions
-----------------
Helicobacter Pylori

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 18 70 ,both gender. Initial diagnosis of stomach Helicobacter pylori infection or never had Helicobacter pylori infection. Have not received dental care or systemic periodontal basic treatment in the past 1 year. Exclusion Criteria: There is serious organ damage and complications (such as cirrhosis, uremia, etc.), severe or unstable cardiopulmonary or endocrine diseases. Ongoing use of antiulcer medications (including PPIs taken within 2 weeks before Helicobacter pylori infection testing), antibiotics, or bismuth complexes (more than 3 times/week before screening). Those with severe oral diseases and malignant tumors of the mouth. Previously had upper gastrointestinal surgery. Refusal to sign informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Both gastric and oral Helicobacter pylori are negative<br> | |
| Negative for Helicobacter pylori for gastric and positive for Helicobacter pylori for oral cavity<br> | |
| Positive for Helicobacter pylori for gastric and negative for Helicobacter pylori for oral cavity<br> | |
| Both gastric and oral Helicobacter pylori are positive<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Positive rate of oral Helicobacter pylori | The oral Helicobacter pylori test is performed using the Helicobacter pylori test kit | 7 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Oral Helicobacter Pylori, Helicobacter Pylori Gastric
Osseodensification Plus Platelet Rich Fibrin With Simultaneous Implant Installation in Closed Sinus Lift

Study Overview
=================
Brief Summary
-----------------
12 patients with indirect sinus lift will be selected with RBH&gt;5mm , surgical procedure =osseodensification + Prf+ implant . versah drilling system (osseodensefication technique )will be used , moreover Prf will be prepared by Blood collected in PRF tubes from patients then centrifuge (1300rpm ,14min ) . primary stability will be measured using Resonance Frequency Analysis by Osstellimmediately and after 6 Mn . CBCT will be taken before surgery , perioapical x-ray immediately after surgery and CBCT at 6m follow up to be apple to see the differences regarding bone quality and volume.

Official Title
-----------------
Osseodensification Plus Platelet Rich Fibrin With Simultaneous Implant Installation in Closed Sinus Lift : A Randomized Control Trial.

Conditions
-----------------
Oral Sinus

Intervention / Treatment
-----------------
* Procedure: prf + osseodensification


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - medically fit non pregnant no sinus pathology Exclusion Criteria: young patients under 18 sinus pathology

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Test group<br>Implant therapy and closed sinus lifting with A-PRF | Procedure: prf + osseodensification<br>* prf+ osseodensification in close sinus lift<br>* Other names: platelet concentrates,;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| secondary stability of implant | by osstel | 6 months | 
| bone density | measuring and evaluating bone density by cbct | 6 months |
Proteomics and Genomics Combined With CT to Predict CVD

Study Overview
=================
Brief Summary
-----------------
This study evaluates plaque progression and characteristics in patients with coronary atherosclerosis.

Official Title
-----------------
Proteomics and Genomics Combined With CT to Predict CVD

Conditions
-----------------
Coronary Artery Disease Progression

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients between 50 and 75 years old Subjects at intermediate to high risk for ASCVD Asymptomatic patients without cardiac chest pain Evidence of atherosclerosis on baseline CCTA Exclusion Criteria: Renal insufficiency, defined as eGFR < 30 ml/min History of cardiovascular events (myocardial infarction, peripheral artery disease and ischemic stroke) Use of lipid lowering therapy other than statin, ezetimibe or bempedoic acid monotherapy Change in lipid lowering therapy in the last 6 months Use of more than two antihypertensive agents No coronary atherosclerosis at baseline imaging Active malignancy requiring treatment Atrial fibrillation Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Coronary Artery Disease Progression |  | Through study completion, between 130-156 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of obstructive stenosis |  | Through study completion, between 130-156 weeks | 
| Progression in number of significant (>50%) and severe (>70%) stenoses |  | Through study completion, between 130-156 weeks | 
| Total plaque volume progression |  | Through study completion, between 130-156 weeks | 
| Calcified plaque volume progression |  | Through study completion, between 130-156 weeks | 
| Non-calcified plaque volume progression |  | Through study completion, between 130-156 weeks | 
| Low-attenuation plaque volume progression |  | Through study completion, between 130-156 weeks | 
| Change in Pericoronary Adipose Tissue CT-Attenuation |  | Through study completion, between 130-156 weeks | 
| CAD-RADS progression (yes/no) |  | Through study completion, between 130-156 weeks | 
| Progression in number of high-risk plaque characteristics (yes/no) |  | Through study completion, between 130-156 weeks |
A Study of a Novel Scheimpflug Device in Diagnosing Keratoconus

Study Overview
=================
Brief Summary
-----------------
Comparison of the screening and diagnosis ability of the novel Scheimpflug-based tomography device (Scansys) with Pentacam and the Scheimpflug-based biomechanics device (Corvis ST) for keratoconus.

Official Title
-----------------
Evaluation of a Novel Scheimpflug Device for Detection of Early Keratoconus

Conditions
-----------------
Scansys, Pentacam, Corvis ST, Keratoconus, Subclinical Keratoconus

Intervention / Treatment
-----------------
* Other: Pentacam, Corvis ST and Scansys


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Best corrected visual acuity (BCVA) ≥ 20/20; No other eye diseases except myopia and astigmatism; The cornea was transparent, and there was no cloud or pannus; Exclusion Criteria: The presence of ocular diseases other than myopia and keratoconus; Ocular trauma; Previous ocular surgery; Patients were required to stop wearing soft contact lenses for at least 2 weeks and rigid contact lenses for at least 4 weeks before examination; Pregnant and lactating women;
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Normal control group<br> | Other: Pentacam, Corvis ST and Scansys<br>* morphological and biomechanical parameters of corneal were obtain by Scansys, Pentacam and Corvis ST<br>|
| Subclinical keratoconus<br> | Other: Pentacam, Corvis ST and Scansys<br>* morphological and biomechanical parameters of corneal were obtain by Scansys, Pentacam and Corvis ST<br>|
| Keratoconus<br> | Other: Pentacam, Corvis ST and Scansys<br>* morphological and biomechanical parameters of corneal were obtain by Scansys, Pentacam and Corvis ST<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| screening and diagnosis ability | Calculate the cut-off values, sensitivity and specificity of parameters measured by Pentacam, Corvis ST and Scansys in diagnosing keratoconus. Use Receiver operating characteristic curves (ROC) to analyze the optimal parameters to distinguish between the three groups. | one year |
Optic Nerve Course Variants in Nepali Population

Study Overview
=================
Brief Summary
-----------------
A retrospective study was conducted on 367 patients. CT PNS and head of the patients were evaluated for type of course of optic nerve according to DeLano's Classification.

Detailed Description
-----------------
A retrospective study was conducted on 367 patients aged 13 years and above. Four investigators, each with 2 to 6 years of experience in the field of radiology, evaluated computed tomography scans of the paranasal sinuses and the head of these patients. The optic nerves were classified into four types based on DeLano's classification, and their respective prevalence rates were determined. Additionally, the prevalence of optic nerve dehiscence and pneumatization of the anterior clinoid process was assessed.

Official Title
-----------------
Evaluation of Variations of Optic Nerve Course in Relation to Posterior Paranasal Sinuses in MDCT at a Tertiary Care Center of Nepal

Conditions
-----------------
Optic Nerve

Intervention / Treatment
-----------------
* Other: No intervention done


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing NCCT PNS and Head for chronic rhinosinusitis, headache and vertigo Exclusion Criteria: Patient less than 13 years age Patients with recent trauma Patient with large mass/ extensive polyposis

Ages Eligible for Study
-----------------
Minimum Age: 13 Years
Maximum Age: 94 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Rhinosinusitis<br>Patients with rhinosinusitis | Other: No intervention done<br>* No interventions done<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of different types of optic nerve course | Type 4 course is more prevalent than type 3 course | 1.5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Optic Nerve Course, De Lano's Classification, Anterior Clinoid Process Pneumatization
Application of Serum Bile Acid Profile in the Diagnosis of Gastric Cancer

Study Overview
=================
Brief Summary
-----------------
In this study, the composition and level of serum bile acids in patients with gastric cancer and non-gastric cancer were analyzed by detecting the serum bile acid profile, so as to develop new serological diagnostic methods for early diagnosis and treatment of gastric cancer.

Official Title
-----------------
Application of Serum Bile Acid Profile in the Diagnosis of Gastric Cancer

Conditions
-----------------
Gastric Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 18-70, both gender; The gastric cancer group was early gastric cancer or advanced gastric cancer diagnosed by endoscopic examination and pathological biopsy. The non-gastric cancer group included patients without gastric lesions, superficial gastritis, chronic atrophic gastritis, intestinal metaplasia or dysplasia diagnosed by gastroscopy or pathological biopsy; Informed consent was obtained. Exclusion Criteria: The patients have diseases that affect bile acid metabolism, such as liver cirrhosis, gallstones or inflammatory bowel disease, Behcet's disease, etc; Due to other diseases, the patient took drugs affecting bile acid metabolism, such as cholestyramine, anti-inflammatory Lidan tablets, Danshu capsules, ursodeoxycholic acid, obticholic acid, Schisandrin B, tanshinone ⅡA, Yinzhihuang, etc; Pregnant women; Primary tumors of other systems were diagnosed; Those with poor physiopathological conditions, such as chronic kidney disease requiring long-term dialysis; Patients with mental illness; Patients who have received radiotherapy or surgery previously; Those with poor adherence or difficult to follow up.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| gastric cancer<br> | |
| non-gastric cancer<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum bile acid profile before treatment |  | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| concentration of serum tumor markers before treatment | CEA, CA19-9 and CA12-5 | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
serum bile acid, biomarker
Discard the Curative Causes of Late Onset Epilepsy: the Role of Brain 18F-FDG PET

Study Overview
=================
Brief Summary
-----------------
Etiology and cognitive prognosis in late onset epilepsy differ from young adults epilepsy. At the epilepsy onset, this is crucial to detect potential curative/treatable brain disorders. After classical investigation including morphological brain imaging, EEG, clinical assessment, which added value may have brain FDG PET in the diagnosis and prognosis evaluation?

Official Title
-----------------
Discard the Curative Causes of Late Onset Epilepsy: the Role of Brain 18F-FDG PET

Conditions
-----------------
Late Onset Epilepsy, Alzheimer Disease

Intervention / Treatment
-----------------
* Diagnostic Test: TEP FDG


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: late onset épilepsy patients without lesion epilepsy followed at the CHRU Nancy france Exclusion Criteria: epilepsy explained by cortical lesion severe psychiatric disorders severe addiction (alcool, drugs) no FDG TEP performed no neuropsychological assessement after 2 years epilepsy onset

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: TEP FDG|FDG TEP peformed in clinical routine|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| diagnostic performances | sensibility, specificty, accurracy | 2 years after epilepsy onset | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cognitive prognosis performances | sensibility, specificty, accurracy | 2 years after epilepsy onset | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
FDG PET, cognitive prognosis
Investigating the Experiences of Individuals With Gastric Cancer Participating in Clinical Trials

Study Overview
=================
Brief Summary
-----------------
This study is observational, meaning that it does not include any interventions or new treatments. As a result, there may not be an immediate benefit for the patient with gastric cancer. However, the data collected from this trial can contribute to a better understanding of the factors that affect withdrawal and enrolment rates in gastric cancer clinical trials, and may ultimately lead to improved patient outcomes in the future.

Official Title
-----------------
An Observational Study Evaluating The Experiences of Gastric Cancer Patients In Clinical Trials

Conditions
-----------------
Gastric Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is a minimum of 18 years or older Patient has been diagnosed with gastric cancer Patient has been self-identified as planning to enroll in an observational clinical study Exclusion Criteria: Patient is breastfeeding or pregnant Inability to perform regular electronic reporting Patient does not understand, sign, and return consent form

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients who decide to enroll in a gastric cancer clinical trial |  | 3 months | 
| Rate of patients who remain in a gastric cancer clinical trial to trial completion |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Gastric Cancer, Gastric Cancer Stage
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

Study Overview
=================
Brief Summary
-----------------
A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

Official Title
-----------------
A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus (APRICITY-A)

Conditions
-----------------
Keratoconus

Intervention / Treatment
-----------------
* Combination Product: Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment
* Combination Product: Placebo and sham treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of keratoconus Exclusion Criteria: Minimal corneal thickness < 350 microns Non-keratoconic ectatic disease Contraindications or hypersensitivities to any required study medications Pregnancy or breastfeeding Certain concomitant ocular conditions

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Active Treatment<br>Epithelium-on corneal cross-linking | Combination Product: Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment<br>* Drug: Ribostat riboflavin and sodium iodide ophthalmic solution Device: UV-3000 ultraviolet A light source<br>|
| Placebo Comparator: Control Treatment<br>Placebo and sham for epithelium-on corneal cross-linking | Combination Product: Placebo and sham treatment<br>* Drug: placebo ophthalmic solution Device: UV-3000 light source<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Best Spectacle-Corrected Distance Visual Acuity (BSCDVA) | BSCDVA will be assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. The score ranges from 0 to 100, with a higher score representing better visual functioning. | Baseline to 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vision-related Quality of Life as Assessed by the National Eye Institute 25-Item Visual Function Questionnaire (NEI-VFQ-25) | The score on the NEI-VFQ-25 ranges from 0 to 100, with a higher score indicating greater functioning. | Baseline to 12 months |